Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Study in Healthy Volunteers to Assess the Pharmacokinetics of Midazolam Administered Alone and in Combination With Vandetanib

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Midazolam
Drug: vandetanib

First Posted Date: 2012-03-05

Last Posted Date: 2016-08-29

Lead Sponsor: Sanofi

Target Recruit Count: 16

Registration Number: NCT01544140

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib

Phase 1

Completed

Conditions: Medullary Thyroid Cancer

Interventions: Drug: vandetanib
Drug: ranitidine
Drug: omeprazole

First Posted Date: 2012-02-27

Last Posted Date: 2017-05-02

Lead Sponsor: Sanofi

Target Recruit Count: 34

Registration Number: NCT01539655

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

Safety, Tolerability and Pharmacokinetics of SAR231893 (REGN668) in Healthy Japanese Adult Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: SAR231893 (REGN668)
Drug: placebo

First Posted Date: 2012-02-23

Last Posted Date: 2013-12-06

Lead Sponsor: Sanofi

Target Recruit Count: 32

Registration Number: NCT01537653

Locations: 🇯🇵
Investigational Site Number 392001, Toshima-Ku, Japan

Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: SAR231893 (REGN668) DP1
Biological: SAR231893 (REGN668) DP2

First Posted Date: 2012-02-23

Last Posted Date: 2013-12-06

Lead Sponsor: Sanofi

Target Recruit Count: 30

Registration Number: NCT01537640

Locations: 🇺🇸
Investigational Site Number 840001, Daytona Beach, Florida, United States

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

Phase 1

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: SAR156597
Drug: Placebo (for SAR156597)

First Posted Date: 2012-02-09

Last Posted Date: 2016-02-15

Lead Sponsor: Sanofi

Target Recruit Count: 24

Registration Number: NCT01529853

Locations: 🇺🇸
Investigational Site Number 840010, Charleston, South Carolina, United States
🇨🇱
Investigational Site Number 152003, Santiago, Chile
🇺🇸
Investigational Site Number 840013, New York, New York, United States

and more 18 locations

Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment

Phase 1

Completed

Conditions: Neoplasm Malignant

Interventions: Drug: Cabazitaxel XRP6258

First Posted Date: 2012-02-07

Last Posted Date: 2013-12-04

Lead Sponsor: Sanofi

Target Recruit Count: 25

Registration Number: NCT01527929

Locations: 🇧🇪
Investigational Site Number 056002, Bruxelles, Belgium
🇧🇪
Investigational Site Number 056001, Gent, Belgium
🇳🇱
Investigational Site Number 528002, Utrecht, Netherlands

and more 4 locations

Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Lixisenatide (AVE0010)
Device: Self-injector pen device (OptiClik®)
Drug: Metformin

First Posted Date: 2012-01-25

Last Posted Date: 2016-10-14

Lead Sponsor: Sanofi

Target Recruit Count: 451

Registration Number: NCT01517412

Locations: 🇨🇿
Investigational Site Number 203104, Plzen, Czech Republic
🇵🇱
Investigational Site Number 616106, Bytom, Poland
🇵🇱
Investigational Site Number 616105, Wroclaw, Poland

and more 79 locations

Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Drug: Docetaxel (XRP6976)
Drug: Oxaliplatin (SR96669)
Drug: S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)

First Posted Date: 2012-01-24

Last Posted Date: 2023-12-13

Lead Sponsor: Sanofi

Target Recruit Count: 530

Registration Number: NCT01515748

Locations: 🇰🇷
Administrative Office, Seoul, Korea, Republic of

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Cabazitaxel XRP6258
Drug: Abiraterone acetate
Drug: Prednisone 5 mg

First Posted Date: 2012-01-18

Last Posted Date: 2016-07-28

Lead Sponsor: Sanofi

Target Recruit Count: 38

Registration Number: NCT01511536

Locations: 🇬🇧
Investigational Site Number 826001, Sutton, United Kingdom
🇺🇸
Investigational Site Number 840002, New Haven, Connecticut, United States
🇺🇸
Investigational Site Number 840001, San Francisco, California, United States

and more 1 locations

Safety, Tolerability and Pharmacokinetics of SAR113945 in Japanese Patients With Knee Osteoarthritis

Phase 1

Completed

Conditions: Knee Osteoarthritis

Interventions: Drug: SAR113945
Drug: placebo

First Posted Date: 2012-01-18

Last Posted Date: 2012-10-01

Lead Sponsor: Sanofi

Target Recruit Count: 24

Registration Number: NCT01511549

Locations: 🇯🇵
Investigational Site Number 392001, Osaka-Shi, Japan

Home Terms & Conditions Privacy Policy